Evidence map›Paper›PMID 33354514›Full record

ArticleMolecular genetics and metabolism reports2020

Growth hormone as a rescue treatment in maple syrup urine disease with lessons from pediatric burn literature, case report and brief literature review.

Brooke E Kimbrell, Faith Hicks, Cortney B Foster, Omayma A Kishk, Sara A Quinteros-Fernandez, Maria Eleni Nikita, Carol L Greene

Open access · goldAbstract readCase Reports
In one paragraph

Article in Molecular genetics and metabolism reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Brooke E Kimbrell1501 Kennewick Rd, Baltimore, MD 21218, United States of America.
Faith HicksPrisma Health Systems, Greenville, SC 29605, United States of America.
Cortney B FosterDivision of Pediatric Critical Care, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America.
Omayma A KishkDepartment of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21218, United States of America.
Sara A Quinteros-FernandezDepartment of Nutrition, University of Maryland Medical Center, Baltimore, MD 21201, United States of America.
Maria Eleni NikitaDivision of Pediatric Endocrinology, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America.
Carol L GreeneDivision of Genetics, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America.
University of Maryland, Baltimore · USUniversity of Maryland Medical Center · USKennedy Krieger Institute · USPrisma Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maple Syrup Urine Disease (MSUD) is a rare inherited disorder of branched chain amino acid metabolism characterized by cerebral edema and death in uncorrected metabolic crisis. It is conventionally treated with intensive nutritional therapy to prevent and correct metabolic crisis. This paper reports the use of growth hormone as a pharmacologic rescue agent in the case of an 11-year-old male with MSUD and metabolic crisis refractory to standard interventions. The initiation of short courses of growth hormone correlated with corrected mental status, resolution of metabolic acidosis, and improvement in plasma leucine levels on two occasions during an admission to the pediatric intensive care unit. This is the first known case report of the use of growth hormone in MSUD since contemporary dietary management became available. The discussion includes a literature review of the use of growth hormone in inherited diseases of amino acid metabolism and a brief discussion of protein anabolic pharmacotherapeutic agents shown to improve net protein balance in pediatric burn patients. We propose that growth hormone and other protein anabolic agents may be valuable adjuvants to standard therapy in children with inherited metabolic disease.

Indexed as

Anabolic pharmacologyBranched-chain alpha-ketoacid dehydrogenation deficiencyGrowth hormoneInherited metabolic diseaseMaple syrup urine diseaseMetabolic crisis

Identifiers

PMID33354514
PMCPMC7744761
OpenAlexW3110687634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.